[Pharmacotherapeutical action on arteriosclerotic vascular diseases with benzarone (author's transl)].

Abstract

We report the results of a pilot study to evaluate the therapeutical efficiency of Benzarone in a time span of four weeks in 11 male patients with intermittent claudication. Numerous experimental data indicate that there was a statistically significant increase of painless walking distance and a statistically significant decrease of plasma uric acid, cholesterol and triglycerides. Coagulation analyses furthermore show an increase of the factor VIII activity and the plasminogen levels. For the first time, positive results were shown with Benzarone in patients with intermittent claudication.

• Authors: H Mörl, C Diehm, R Zimmermann, G Schöffel, E Walter
• Journal: MMW, Munchener medizinische Wochenschrift (MMW Munch Med Wochenschr) Vol. 122 Issue 8 Pg. 277-80 (Feb 22 1980) ISSN: 0341-3098 [Print] Germany
• Vernacular Title: Pharmakotherapeutische Beeinflussung arteriosklerotischer Gefässerkrankungen durch Benzaron.
• PMID: 6767967 (Publication Type: English Abstract, Journal Article)

Chemical References

• Benzofurans
• Triglycerides
• Uric Acid
• Benzbromarone
• Factor VIII
• Plasminogen
• Cholesterol

Topics

• Arteriosclerosis (drug therapy)
• Benzbromarone (therapeutic use)
• Benzofurans (therapeutic use)
• Cholesterol (blood)
• Factor VIII
• Humans
• Intermittent Claudication (drug therapy)
• Male
• Middle Aged
• Plasminogen
• Triglycerides (blood)
• Uric Acid (blood)